Skip to main
LFCR

LFCR Stock Forecast & Price Target

LFCR Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lifecore Biomedical is a positive investment due to their recent high-level commercial execution, strong turnaround strategy and progress, and potential financial impact from recent agreements - including the potential for "meaningful commercial revenue in 2028." In addition, their focus on expense management and business transformation should lead to improved profitability. While there are risks to achieving the target price, we arrived at our target by attaching a 20x multiple to FY/26 adjusted EBITDA estimate and risk factors such as failure to meet revenue or earnings estimates.

Bears say

Lifecore Biomedical is seeing impressive growth opportunities through capacity utilization, demonstrating strong execution of the strategic vision of CEO Paul Josephs and his team. Despite historical limitations in its business scope, Lifecore is now expanding to reach a larger vision. However, there are risks, such as failure to meet revenue or earnings estimates, that may impact achieving projected price targets. The use of EV/EBITDA as a pricing metric also presents potential uncertainties.

LFCR has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lifecore Biomedical Inc (LFCR) Forecast

Analysts have given LFCR a Buy based on their latest research and market trends.

According to 1 analysts, LFCR has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lifecore Biomedical Inc (LFCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.